Annamaria Gulla

List of Publications by Citations

30 papers	1,501 citations	16 h-index	32 g-index
32 ext. papers	1,708 ext. citations	4.7 avg, IF	4.07 L-index

#	Paper	IF	Citations
30	Mir-34: a new weapon against cancer?. *Molecular Therapy - Nucleic Acids*, **2014**, 3, e194	10.7	358
29	Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. *Clinical Cancer Research*, **2012**, 18, 6260-70	12.9	185
28	Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. *Clinical Cancer Research* , **2013**, 19, 2096-106	12.9	165
27	In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. *Oncotarget*, **2013**, 4, 242-55	3.3	109
26	In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. *PLoS ONE*, **2014**, 9, e90005	3.7	90
25	Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. *Oncotarget*, **2014**, 5, 3039-54	3.3	80
24	A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. *Clinical Cancer Research*, **2016**, 22, 1222-33	12.9	79
23	Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts. *Oncotarget*, **2015**, 6, 27343-58	3.3	78
22	In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells. *PLoS ONE*, **2014**, 9, e89659	3.7	72
21	Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities. *Frontiers in Oncology*, **2014**, 4, 348	5.3	48
20	Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. *Blood*, **2018**, 132, 1050-1063	2.2	40
19	Transferrin-conjugated SNALPs encapsulating 2′-O-methylated miR-34a for the treatment of multiple myeloma. *BioMed Research International*, **2014**, 2014, 217365	3	38
18	Mir-221/222 are promising targets for innovative anticancer therapy. *Expert Opinion on Therapeutic Targets*, **2016**, 20, 1099-108	6.4	36
17	Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. *Leukemia*, **2018**, 32, 2626-2635	10.7	31
16	Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. *Blood*, **2017**, 129, 2233-2245	2.2	25
15	Multiple myeloma: the (r)evolution of current therapy and a glance into future. *Haematologica*, **2020**, 105, 2358-2367	6.6	21
14	Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. *Blood Cancer Discovery*, **2021**, 2, 468-483	7	15

List of Publications

13	The Non-Coding RNA Landscape of Plasma Cell Dyscrasias. *Cancers*, **2020**, 12,	6.6	14
12	Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities. *Frontiers in Oncology*, **2020**, 10, 606368	5.3	7
11	Identification of a Novel Long Intergenic Noncoding RNA - Linc00936, with Significant Impact on Multiple Myeloma Cell Growth Via mTOR Pathway Inhibition. *Blood*, **2015**, 126, 504-504	2.2	2
10	Loss-of-Function of Gabarap Impairs Bortezomib-Induced Anti-Tumor Immunity in Multiple Myeloma: Clinical Application. *Blood*, **2019**, 134, 134-134	2.2	2
9	Targeting Myeloma Cell Metabolism Via Disruption of the Lnc-17-92 Transcriptional Program: Druggable New Vulnerability in Multiple Myeloma. *Blood*, **2019**, 134, 317-317	2.2	1
8	Targeting Free Light Chain Secretion Via Botulinum Neurotoxin Is a Novel Therapeutic Strategy in AL Amyloidosis By Inducing a Terminal Unfolded Protein Response. *Blood*, **2021**, 138, 1576-1576	2.2	1
7	Dual BCL-2/BCL-XL Inhibitor Pelcitoclax (APG-1252) Overcomes Intrinsic and Acquired Resistance to Venetoclax in Multiple Myeloma Cells. *Blood*, **2021**, 138, 2655-2655	2.2	1
6	Gabarap Loss Mediates Immune Escape in High Risk Multiple Myeloma. *Blood*, **2021**, 138, 891-891	2.2	1
5	ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. *Blood Cancer Discovery*, **2021**, 2, 338-353	7	1
4	RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma. *Blood*, **2020**, 136, 20-21	2.2	
3	Identifying Long Noncoding RNA Dependencies Using CRISPR Interference (CRISPRi)-Based Platform in Multiple Myeloma. *Blood*, **2021**, 138, 894-894	2.2	
2	The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche. *Blood*, **2019**, 134, 507-507	2.2	
1	Inhibition Of Mir-21 In HS-5 Bone Marrow Stromal Cells In The Presence Of Multiple Myeloma cells Restores RANKL/OPG Ratio: A Potential Therapeutic Approach For Myeloma-Related Bone Disease. *Blood*, **2013**, 122, 683-683	2.2	